DanielleRArmasMD

Physician

Dr. Armas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Mayo Clinic College of Medicine and Science (Rochester)Residency, Family Medicine, 2006 - 2009
Mayo Clinic College of MedicineClass of 2006

Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2010-2013
Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2010-2013

An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201) Start of enrollment: 2021 Jul 16
Completed
Phase 2
Roles: Contact
A Study of TAK-227 in Healthy Adults Start of enrollment: 2023 May 25
Completed
Phase 1
Roles: Principal Investigator

PubMed

1 citations
Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants.
Shichang Miao, Pirow Bekker, Danielle Armas, Mary Lor, Ryuzo Hanada
Clinical Pharmacology in Drug Development. 2024-09-01
1 citations
A phase I thorough QT/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participants.
Shichang Miao, Peter Staehr, Ezra Tai, Borje Darpo, Hongqi Xue
Clinical and Translational Science. 2024-07-01
3 citations
Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug-Drug Interaction of Avacopan in 2 Open-Label Studies in Healthy Participants.
Shichang Miao, Pirow Bekker, Danielle Armas, Mary Lor, Yanyan Han
Clinical Pharmacology in Drug Development. 2024-05-01

Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)September 1st, 2021
Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy SubjectsSeptember 7th, 2017